基于暂时连接技术的长效生长激素临床应用专家指导意见OA

Growth hormone deficiency(GHD)is one of the leading endocrine causes of short stature in children and adolescents.Exogenous supplementation with recombinant human growth hormone(rhGH)is currently the main treatment option.While daily rhGH is clinically effective,long-term daily injections pose a substantial treatment burden and compliance challenges on both patients and caregivers.In recent years,long-acting growth hormone(LAGH)products(weekly administration)have become available,substantially reducing dosing frequency and thereby improving compliance.However,LAGH products based on different long-acting technologies vary markedly in molecular structure,drug properties,mechanism of action,pharmacokinetics/pharmacodynamics,clinical application and dosing regimens,as well as in safety monitoring requirements.Clinical experience in these products remains limited,and standardized guidance is lacking.Transient conjugation technology is an innovative technology for prolonging the duration of growth hormone;it has been widely used clinically in the United States and Europe,but its application experience and related research in China remain relatively limited.To optimize treatment strategies for GHD and enhance patients' treatment experience,we have developed this expert guidance on the clinical application of LAGH based on transient conjugation technology.This expert guidance addresses the developmental background of LAGH,outlines transient conjugation technology,provides an evidence-based interpretation of lonapegsomatropin(a LAGH developed using this technology),and offers specific recommendations on clinical application.